Pharvaris (PHVS) 6-K 14 Aug 24 2024 Q2 Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update Financial data

Cover Page

Cover Page	6 Months Ended
	Jun. 30, 2024
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Registrant Name	Pharvaris N.V.
Entity Central Index Key	0001830487
Current Fiscal Year End Date	--12-31

Condensed consolidated statemen

Condensed consolidated statement of loss and other comprehensive income - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Profit or loss [abstract]
Research and development expenses	€ (23,067,934)	€ (14,681,935)	€ (41,580,950)	€ (28,426,366)
General and administrative expenses	(11,314,067)	(7,773,430)	(21,112,910)	(15,105,026)
Total operating expenses	(34,382,001)	(22,455,365)	(62,693,860)	(43,531,392)
Finance income/(expense)	4,721,551	651,670	5,299,771	(842,595)
Loss before income tax	(29,660,450)	(21,803,695)	(57,394,089)	(44,373,987)
Income taxes	(70,623)	(94,178)	(355,740)	(154,835)
Net Loss	(29,731,073)	(21,897,873)	(57,749,829)	(44,528,822)
Items that may be reclassified to profit or loss:
Exchange gains/(losses) arising on translation of foreign operations	21,106	1,624	56,739	(28,885)
Total comprehensive loss attributable to:
Equity holders of the Company	€ (29,709,967)	€ (21,896,249)	€ (57,693,090)	€ (44,557,707)
Loss per share attributable to the equity holders of the Company during the periods
Basic loss per share	€ (0.55)	€ (0.63)	€ (1.07)	€ (1.3)
Diluted loss per share	€ (0.55)	€ (0.63)	€ (1.07)	€ (1.3)

Condensed consolidated statem_2

Condensed consolidated statement of financial position - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Non-current assets
Property, plant and equipment	€ 258,551	€ 223,678
Right of use assets	133,981	231,893
Deferred tax assets	346,621	387,529
Current assets
Receivables	515,304	423,486
Other current assets	5,921,334	5,580,704
Cash and cash equivalents	343,574,386	391,231,637
Current tax receivable	1,095,589	615,538
Total assets	351,845,766	398,694,465
Equity
Share capital	6,480,925	6,274,833
Share premium	619,047,642	615,811,986
Other reserves	31,965,648	27,894,796
Currency translation reserve	42,155	(14,584)
Accumulated loss	(324,767,645)	(265,918,628)
Total equity	332,768,725	384,048,403
Long term liabilities
Non-current lease liability	43,750	43,564
Current liabilities
Trade and other payables	2,968,446	2,909,725
Accrued liabilities	15,857,612	11,067,510
Current lease liability	96,628	195,341
Current tax payable	110,605	429,922
Total liabilities	19,077,041	14,646,062
Total equity and liabilities	€ 351,845,766	€ 398,694,465

Condensed consolidated statem_3

Condensed consolidated statement of changes in equity - EUR (€)	Total	Share capital [member]	Share premium [member]	Other reserves [member]	Currency translation reserve [member]	Accumulated losses [member]
Beginning balance at Dec. 31, 2022	€ 149,259,030	€ 4,057,976	€ 289,177,197	€ 20,169,459	€ 43,290	€ (164,188,892)
Net Loss	(44,528,822)					(44,528,822)
Issue of share capital	64,084,953	834,161	63,250,792
Transaction costs on issue of shares	(209,870)		(209,870)
Currency translation reserve	(28,885)				(28,885)
Settlement of share-based payments	(145,653)	6,614	1,213,329	(1,219,943)		(145,653)
Share-based payments	5,299,814			5,299,814
Ending balance at Jun. 30, 2023	173,730,567	4,898,751	353,431,448	24,249,330	14,405	(208,863,367)
Beginning balance at Dec. 31, 2023	384,048,403	6,274,833	615,811,986	27,894,796	(14,584)	(265,918,628)
Net Loss	(57,749,829)					(57,749,829)
Issue of share capital	12,609	165,000	(165,000)	12,609
Transaction costs on issue of shares	592,000		592,000
Currency translation reserve	56,739				56,739
Settlement of share-based payments	(479,500)	41,092	2,808,656	(2,230,060)		(1,099,188)
Share-based payments	6,288,303			6,288,303
Ending balance at Jun. 30, 2024	€ 332,768,725	€ 6,480,925	€ 619,047,642	€ 31,965,648	€ 42,155	€ (324,767,645)

Condensed consolidated statem_4

Condensed consolidated statement of cash flows $ in Millions	6 Months Ended
	Jun. 30, 2024 EUR (€)	Jun. 30, 2023 EUR (€)
Operating activities
Loss before tax	€ (57,394,089)	€ (44,373,987)
Non-cash adjustments to reconcile loss before tax to net cash flows from operations:
Share-based payment expense	6,288,303	5,299,814
Depreciation expense	135,032	123,593
Net foreign exchange (gain) loss	(3,146,528)	928,172
Finance income	(2,160,801)	(85,173)
Changes in working capital:
Decrease (increase) in receivables	(91,786)	48,169
Increase in other current assets	(300,336)	(4,855,629)
Increase (decrease) trade and other payables	58,721	(1,522,938)
Increase (decrease) in accrued liabilities	3,690,913	(948,917)
Income taxes paid	(1,114,758)	(383,953)
Received interest	2,120,352	83,384
Net cash flows used in operating activities	(51,914,977)	(45,687,465)
Investing activities
Purchase of property, plant and equipment	(70,844)	(54,114)
Net cash flows used in investing activities	(70,844)	(54,114)
Financing activities
Proceeds from issue of shares	632,737	64,084,953
Transaction costs on issue of shares ,net	592,968	(210,473)
Payment of principal portion of lease liabilities	(107,239)	(90,249)
Net cash flows provided by financing activities	1,118,466	63,784,231
Net (decrease) increase in cash and cash equivalents	(50,867,355)	18,042,652
Cash and cash equivalents at the beginning of the period	391,231,637	161,837,429
Effect of exchange rate changes	3,210,104	(691,322)
Cash and cash equivalents at the end of the period	€ 343,574,386	€ 179,188,759

Corporate and Group information

Corporate and Group information	6 Months Ended
	Jun. 30, 2024
Disclosure Of Corporate And Group Information [Abstract]
Corporate and Group information	1 . Corporate and Group information This section provides general corporate and group information about Pharvaris N.V. and its subsidiaries. 1.1 Corporate information Pharvaris N.V. was incorporated on September 30, 2015 and is based in Leiden, the Netherlands. The Company’s registered office is located at Emmy Noetherweg 2, Leiden. The Company is registered at the Chamber of Commerce under file number 64239411. Pharvaris is a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The unaudited condensed consolidated interim financial statements of Pharvaris N.V. (the “Company” or “Pharvaris”) and its subsidiaries (collectively, “The Group”) as of June 30, 2024, and December 31, 2023, and for the three and six months ended June 30, 2024 and 2023 were authorized for issue in accordance with a resolution of the directors on August 13, 2024. 1.2 Group information Subsidiaries The unaudited condensed consolidated interim financial statements of the Group include: Country of % of equity interest as Name Legal seat incorporation 2024 2023 Pharvaris Holdings B.V. Leiden The Netherlands 100 % 100 % Pharvaris Netherlands B.V. Leiden The Netherlands 100 % 100 % Pharvaris GmbH Zug Switzerland 100 % 100 % Pharvaris, Inc. Delaware United States of America 100 % 100 % The ultimate parent company of the Group is Pharvaris N.V., which is based in the Netherlands.

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jun. 30, 2024
Disclosure of voluntary change in accounting policy [abstract]
Summary of significant accounting policies	2. Summary of significant accounting policies 2.1 Basis of preparation The unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board (IASB) and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended December 31, 2023 (“last annual financial statements”). These unaudited condensed consolidated interim financial statements do not include all the information required for a complete set of financial statements prepared in accordance with IFRS as issued by the IASB. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance since the last annual financial statements. The unaudited condensed consolidated interim financial statements have been prepared on a historical cost basis. Unless otherwise stated, the unaudited condensed consolidated interim financial statements are presented in euros and all values are rounded to the nearest EUR (€), except per share amounts. 2.2 Going concern Management assessed the Company’s ability to fund its operations for a period of at least one year after the date th e financial statements are issued. Management has not identified a material uncertainty relating to the Company’s ability to continue as a going concern for a period of at least a year from the issuance of these financial statements. The financial statements of the Company have been prepared on the basis of the going concern assumption based on its existing funding, taking into account the Company’s current cash position and the projected cash flows based on the activities under execution on the basis of Pharvaris’ business plan and budget. 2.3 Use of judgements and estimates In preparing these unaudited condensed consolidated interim financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements. 2.4 Change in material accounting policies The accounting policies applied in these unaudited condensed consolidated interim financial statements are the same as those applied in the consolidated financial statements for the year ended December 31, 2023. New standards and interpretations issued not yet effective In April 2024, the IASB issued IFRS 18 Presentation and Disclosure in Financial Statements (“IFRS 18”) which replaces IAS 1 Presentation of Financial Statements. IFRS 18 requires an entity to classify all income and expenses within its statement of profit or loss into one of five categories: operating; investing; financing; income taxes; and discontinued operations. The first three categories are new. These categories are complemented by the requirement to present subtotals and totals for “operating profit or loss”, “profit or loss before financing income and taxes” and “profit or loss”. IFRS 18, and the amendments to the other standards, is effective for reporting periods beginning on or after January 1, 2027, but earlier application is permitted. The Group is currently evaluating the impact of this amendment. There are no other IFRS or IFRIC interpretations that are not yet effective and that are expected to have a material impact to the interim consolidated financial statements.

Research and development expens

Research and development expenses	6 Months Ended
	Jun. 30, 2024
Disclosure Of Detailed Information Research And Development Expenses [Abstract]
Research and development expenses	3. Research and development expenses For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Clinical expenses ( 15,065,644 ) ( 7,629,432 ) ( 22,387,056 ) ( 12,497,879 ) Personnel expenses (Note 5) ( 6,450,500 ) ( 4,544,244 ) ( 11,630,976 ) ( 8,761,944 ) Manufacturing costs ( 1,572,017 ) ( 736,427 ) ( 4,135,971 ) ( 2,643,513 ) Nonclinical expenses 130,020 ( 1,667,811 ) ( 1,705,446 ) ( 4,419,009 ) License costs — — ( 1,500,000 ) — Intellectual Property costs ( 109,793 ) ( 104,021 ) ( 221,501 ) ( 104,021 ) ( 23,067,934 ) ( 14,681,935 ) ( 41,580,950 ) ( 28,426,366 ) Research and development expenses are currently not capitalized but are recorded in the unaudited condensed consolidated statements of profit or loss and other comprehensive loss because the recognition criteria for capitalization are not met. Clinical expenses include costs of conducting and managing our sponsored clinical trials, including clinical investigator cost, costs of clinical sites, and costs for CRO’s assisting with our clinical development programs. Nonclinical expenses include costs of our outsourced discovery, preclinical and nonclinical development studies. Manufacturing expenses include costs related to manufacturing of active pharmaceutical ingredients and manufacturing of the products used in our clinical trials and research and development activities.

General and administrative expe

General and administrative expenses	6 Months Ended
	Jun. 30, 2024
Disclosure Of Detailed Information General And Administrative Expenses [Abstract]
General and administrative expenses	4. General and administrative expenses For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Personnel expenses (Note 5) ( 4,407,998 ) ( 3,434,343 ) ( 7,678,193 ) ( 6,735,927 ) Professional fees ( 2,155,727 ) ( 1,294,705 ) ( 3,332,956 ) ( 2,177,175 ) Facilities, communication & office expenses ( 1,466,955 ) ( 1,419,334 ) ( 3,147,222 ) ( 2,910,607 ) Accounting, tax and auditing fees ( 850,599 ) ( 537,961 ) ( 2,104,685 ) ( 897,314 ) Consulting fees ( 732,951 ) ( 126,447 ) ( 859,476 ) ( 304,316 ) Travel expenses ( 399,111 ) ( 455,717 ) ( 1,023,140 ) ( 778,450 ) Other expenses ( 1,300,726 ) ( 504,923 ) ( 2,967,238 ) ( 1,301,237 ) ( 11,314,067 ) ( 7,773,430 ) ( 21,112,910 ) ( 15,105,026 ) Since 2022, the Group entered into a number of short-term rental arrangements, the expenses are included in "Other expenses". Depreciation expense in the six months ended June 30, 2024 and 2023 was € 0.1 million and € 0.1 million, respectively, which related to property, plant and equipment and leases and is included in the 'Other expenses' line.

Personnel expenses

Personnel expenses	6 Months Ended
	Jun. 30, 2024
Personnel Expenses [Abstract]
Personnel expenses	5. Personnel expenses For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Wages and salaries ( 5,953,069 ) ( 4,618,862 ) ( 11,023,525 ) ( 8,823,246 ) Pension charges ( 357,282 ) ( 271,140 ) ( 751,915 ) ( 560,023 ) Other social security charges ( 660,711 ) ( 371,658 ) ( 1,245,426 ) ( 814,788 ) Share-based payments ( 3,887,436 ) ( 2,716,927 ) ( 6,288,303 ) ( 5,299,814 ) ( 10,858,498 ) ( 7,978,587 ) ( 19,309,169 ) ( 15,497,871 ) The average number of staff (in FTEs) employed by the Group in the six months ended June 30, 2024 was 83 (2023: 68 ).

Finance income_(expense)

Finance income/(expense)	6 Months Ended
	Jun. 30, 2024
Disclosure Of Financial Income [Abstract]
Finance income/(expense)	6. Finance income/(expense) For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Foreign exchange differences 2,616,719 667,710 3,138,970 ( 927,768 ) Interest income over bank balances 2,114,635 ( 11,161 ) 2,178,556 95,366 Other finance expenses ( 9,803 ) ( 4,879 ) ( 17,755 ) ( 10,193 ) 4,721,551 651,670 5,299,771 ( 842,595 )

Income taxes

Income taxes	6 Months Ended
	Jun. 30, 2024
Income Taxes [Abstract]
Income taxes	7. Income taxes Income taxes are accounted for in line with IAS 34. The interim period is considered part of a larger financial year, where the income tax is recognized in each interim period based on the best estimate of the weighted average annual income tax rate expected for the full financial year. The estimated tax expenses are determined based on a full-year basis (P&L) and subsequently allocated using the expected full year effective tax rate. The discrete items are recognized in full in the interim period in which they emerge. In the total interim tax charge, no distinction is made between current and deferred tax expenses/ income. For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Income tax expense ( 70,623 ) ( 94,178 ) ( 355,740 ) ( 154,835 ) Income tax expense ( 70,623 ) ( 94,178 ) ( 355,740 ) ( 154,835 ) The tax expense over the three and six months ended June 30, 2024 and 2023 relates to the Company's U.S. and Dutch subsidiaries as the result of a cost-plus agreement between the Company's principal entity and the U.S. and the Dutch subsidiaries, resulting in an estimated taxable profit in the U.S. and the Netherlands. Reconciliation of income tax benefit at statutory tax rate and the income tax expense as reported in the unaudited condensed consolidated statement of profit or loss and other comprehensive income is as follows: For the three months ended June 30, For the six months ended 2024 2023 2024 2023 € € € € Loss before income tax ( 29,660,450 ) ( 21,803,695 ) ( 57,394,089 ) ( 44,373,987 ) Income tax against statutory rate in The Netherlands ( 25.8 %) 7,652,396 5,625,353 14,807,675 11,448,489 Effect of tax rates in other countries ( 4,260,352 ) ( 3,135,934 ) ( 8,412,880 ) ( 6,380,538 ) Deferred tax assets recognition effects ( 3,224,214 ) ( 2,473,007 ) ( 6,007,203 ) ( 4,989,138 ) Non-deductible expenses ( 238,743 ) ( 110,591 ) ( 573,609 ) ( 233,648 ) Prior period adjustments 290 — ( 169,723 ) — Total tax charge ( 70,623 ) ( 94,178 ) ( 355,740 ) ( 154,835 ) Income tax expense is recognized based on management’s estimate of the weighted average effective annual income tax rate expected for the full financial year, bearing in mind the impact of non-discrete and discrete items. Non discrete items in the income tax expense are recognized based on management’s estimate of the weighted average effective annual income tax rate expected for the full financial year. Discrete items in the income tax expense are recognized at the applicable statutory tax rate. The (estimated) average annual tax rate used for the six months ended June 30, 2024 was ( 0.6 % ) , compared to ( 0.3 %) for the six months ended June 30, 2023. The current period losses for which no deferred tax asset has been recognized mainly consists of the unrecognized tax effect of losses incurred in Switzerland. The differences in the overseas tax rates are due to the lower tax rate in Switzerland compared to the statutory income tax rate in the Netherlands. Pharvaris N.V. is the head of the fiscal unity including Pharvaris Netherlands B.V. and Pharvaris Holdings B.V. Deferred tax Deferred taxes have been recognized to the extent that management concludes that there is sufficient probability as per IAS 12 that there will be future taxable profits available in the foreseeable future against which the unused tax losses and deductible temporary differences can be utilized. Deferred tax assets relating to losses carried forward have not been recognized, and deferred tax assets on deductible temporary differences in excess of deferred tax liabilities on taxable temporary differences have not been recognized in the consolidated statement of profit and loss and other comprehensive income for the Dutch fiscal unity.

Property, plant and equipment

Property, plant and equipment	6 Months Ended
	Jun. 30, 2024
Disclosure of detailed information about property, plant and equipment [abstract]
Property, plant and equipment	8. Property, plant and equipment June 30, 2024 December 31, 2023 Net book value € € Balance at beginning of period 223,678 193,474 Additions 70,844 90,051 Depreciation expenses ( 35,971 ) ( 59,847 ) Balance at end of period 258,551 223,678 June 30, 2024 December 31, 2023 Cumulative depreciation € € As of January 1, ( 125,373 ) ( 65,526 ) Depreciation ( 35,971 ) ( 59,847 ) Balance at end of period ( 161,344 ) ( 125,373 ) June 30, 2024 December 31, 2023 Cumulative Costs € € Balance at beginning of period 349,051 259,000 Additions 70,844 90,051 Balance at end of period 419,895 349,051 During the six months ended June 30, 2024 , the Group acquired assets with a cost of € 0.1 million (December 31, 2023: € 0.1 million). The acquisitions were mainly related to equipment, tools and installations.

Leases

Leases	6 Months Ended
	Jun. 30, 2024
Disclosure Of Leases [Abstract]
Leases	9. Leases The following table provides information about the Group’s right-of-use assets: June 30, December 31, 2023 € € Balance at beginning of period 231,893 432,965 Addition — ( 3,302 ) Depreciation charges ( 99,062 ) ( 197,770 ) Impact of transaction of foreign currency 1,150 — Balance at end of period 133,981 231,893 The following table provides information about the Group’s lease liabilities at June 30, 2024: June 30, December 31, € € Office leases ( 140,378 ) ( 238,905 ) Total lease liability ( 140,378 ) ( 238,905 ) Current portion ( 96,628 ) ( 195,341 ) Non-current portion ( 43,750 ) ( 43,564 ) Office leases consist of a lease agreement entered into on June 1, 2021 for office space in Lexington, United States of America (the " U.S."), which has ended as of June 30, 2024 and a lease entered into on December 1, 2022, for offices in Leiden, The Netherlands. Both leases have lease terms of three years and were assessed as being long-term. Cash outflows related to leases during the six months ended June 30, 2024 and 2023, were € 0.1 million and € 0.09 million, respectively.

Receivables

Receivables	6 Months Ended
	Jun. 30, 2024
Disclosure of acquired receivables [abstract]
Receivables	10. Receivables June 30, December 31, € € Current tax receivable 1,095,589 615,538 VAT receivables 515,304 423,486 1,610,893 1,039,024

Other current assets

Other current assets	6 Months Ended
	Jun. 30, 2024
Other Current Assets [Abstract]
Other current assets	11. Other current assets June 30, December 31, € € Prepayments 5,921,334 4,959,889 Other assets — 620,815 5,921,334 5,580,704 Prepayments mainly relate to prepaid insurance, sign-on bonus to personnel, prepaid research and development expenses and rent. Other assets for the year ended December 31, 2023, primarily consisted of deferred transaction costs related to the Group’s in-process equity financing (refer to note 13). The Company deferred the transaction costs related to any in-process financing. Upon recognition of the equity instruments, the related transaction costs are deducted from share premium.

Cash and cash equivalents

Cash and cash equivalents	6 Months Ended
	Jun. 30, 2024
Cash and cash equivalents [abstract]
Cash and cash equivalents	12. Cash and cash equivalents Cash and cash equivalents comprise of cash in bank and are not subject to any restriction.

Equity

Equity	6 Months Ended
	Jun. 30, 2024
Equity [abstract]
Equity	13. Equity On June 30, 2024 , the Company’s authorized share capital amounted to € 14.1 million divided into 117,500,000 ordinary shares each with a nominal value of twelve eurocents (€ 0.12 ). As of June 30, 2024 and December 31, 2023, the total number of issued and fully paid shares was 54,007,711 and 52,290,212 , respectively. On June 30, 2024, the issued share capital totaled € 6.5 million (2023: € 4.9 million). On December 31, 2023 , the issued share capital totaled € 6.3 million. In March 2022, the Company filed a Form F-3 Registration Statement and prospectus, allowing the Company to sell up to $ 350 million of its securities with the Securities and Exchange Commission. This Registration Statement was supplemented by a prospectus supplement covering an at-the-market program providing for the sales from time to time of up to $ 75 million of its ordinary shares pursuant to a Sales Agreement with Leerink Partners. As of June 30, 2024 , the Company has sold a total of 593,927 ordinary shares under the sales agreement generating total net proceeds of $ 9.8 million (€ 9.3 million), after deducting $ 0.3 million (€ 0.3 million), which was payable to Leerink Partners as commission in respect of such sales. On April 12, 2024, the Company terminated the March 2022 sales agreement and entered into a new sales agreement with Leerink Partners (the “April 2024 Sales Agreement”), pursuant to which it may sell ordinary shares having an aggregate offering price of up to $ 175 million from time to time through Leerink Partners. In April 2024, the Company filed a Form F-3 ASR Registration Statement (the “F-3 ASR”) and prospectus, allowing the Company to sell an unspecified amount of its securities with the Securities and Exchange Commission. The F-3 ASR was supplemented by a prospectus supplement covering an at-the-market program providing for the sales from time to time of up to $ 175 million of its ordinary shares pursuant to the April 2024 Sales Agreement. In June 2023, the Company sold a total of 6,951,340 ordinary shares, par value €0.12 per share, in a private placement at a purchase price of $10.07 per ordinary share. The sale generated total proceeds of approximately $70 million (€64.2 million). In December 2023, the Company entered into an underwriting agreement with Morgan Stanley & Co. LLC and Leerink Partners, LLC as underwriters, pursuant to which the Company agreed to issue and sell (i) 11,125,000 ordinary shares, par value €0.12 per share and (ii) pre-funded warrants to purchase up to 1,375,000 ordinary shares in an underwritten offering. The offering closed on December 8, 2023, and the Company generated net proceeds of $282.0 million (€261.6 million), after deducting bank fees of $18.0 million (€16.7 million). The pre-funded warrants were exercised in January 2024 for gross exercise proceeds of $ 0.01 million and resulted in issuance of 1,375,000 ordinary shares. In March 2024, the Company received a partial reimbursement for certain of its expenses in connection with the December 2023 offering which have been accounted for in the share premium. Issued shares June 30, December 31, Number of shares Number of shares Ordinary shares 54,007,711 52,290,212 54,007,711 52,290,212

Trade and other payables

Trade and other payables	6 Months Ended
	Jun. 30, 2024
Trade and other payables [abstract]
Trade and other payables	14. Trade and other payables June 30, December 31, € € Trade payables 2,968,446 2,909,725 2,968,446 2,909,725

Accrued liabilities

Accrued liabilities	6 Months Ended
	Jun. 30, 2024
Disclosure of Accrued liabilities [Abstract]
Accrued liabilities	15. Accrued liabilities June 30, December 31, € € Consulting, professional and audit liability 1,933,366 351,064 Clinical accrued liabilities 8,154,946 1,832,590 Manufacturing accrued liabilities 1,108,601 2,079,900 Nonclinical accrued liabilities 618,128 493,907 Personnel related accruals 3,594,600 5,892,087 Other accrued liabilities 447,971 417,962 15,857,612 11,067,510

Risk management activities

Risk management activities	6 Months Ended
	Jun. 30, 2024
Financial Risk Management [Abstract]
Risk management activities	16. Risk management activities The Group’s risk management activities are the same as disclosed in Note 17 of the consolidated financial statements for the year ended December 31, 2023.

Fair values

Fair values	6 Months Ended
	Jun. 30, 2024
Disclosure of fair value measurement of assets [abstract]
Fair values	17. Fair values Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

Share-based payments

Share-based payments	6 Months Ended
	Jun. 30, 2024
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Share-based payments	18. Share-based payments In 2016, the Company implemented an Equity Incentive Plan (the “Plan”) in order to advance the interests of the Company’s shareholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with performance-based incentives that are intended to better align the interests of such persons with those of the Company’s shareholders. This plan has been superseded by the 2021 long term incentive plan (“LTIP”). Set out below is an overview of changes in the Stock Options an d Restricted Stock Units (“RSUs”) during the six months ended June 30, 2024. Stock Options RSUs Outstanding Weighted Outstanding $ Outstanding January 1, 2024 3,830,652 9.46 1,033,814 Granted 785,000 21.68 531,129 Exercised (Vested and Settled) ( 234,694 ) 2.29 ( 157,989 ) Forfeited ( 159,687 ) 15.80 ( 127,543 ) Outstanding June 30, 2024 4,221,271 13.29 1,279,411 On April 11, 2024, a total of 70,000 stock options were granted to members of the Board of Directors with an exercise price of $ 22.31 per share with a final exercise date of April 11, 2034 , unless forfeited or exercised on an earlier date. 100 % of the aggregate number of shares subject to the option shall vest on the 12-month anniversary of the vesting commencement date, subject to the option holder’s continuous service. On April 11, 2024, a total of 485,000 stock options were granted to members of key management with an exercise price of $ 22.31 per share with a final exercise date of April 11, 2034 , unless forfeited or exercised on an earlier date. 25 % of the aggregate number of shares subject to the option shall vest on the 12-month anniversary of the vesting commencement date, and thereafter 1/ 48 th of the aggregate number of Shares subject to the option shall vest on each subsequent monthly anniversary of the vesting commencement date, subject to the option holder’s continuous service through each applicable vesting date. On April 15, 2024 a total of 230,000 stock options were granted to a member of key management with an exercise price of $ 20.15 per share with a final exercise date of April 15, 2034 , unless forfeited or exercised on an earlier date. 25 % of the aggregate number of shares subject to the option shall vest on the 12-month anniversary of the vesting commencement date, and thereafter 1/ 48 th of the aggregate number of shares subject to the option shall vest on each subsequent monthly anniversary of the vesting commencement date, subject to the option holder’s continuous service through each applicable vesting date. As of June 30, 2024, a total number of 4,221,271 stock options are exercisable (June 30, 2023 : 2,065,270 ). The inputs and outputs used in the measurement of the fair value per option at each grant/ measurement date using the Black-Scholes formula (including the related number of options and the fair value of the options) were as follows: April 15, 2024 April 11, April 11, Number of options 230,000 485,000 70,000 Fair value of the options $ 16.37 $ 18.12 $ 18.05 Fair value of the ordinary shares $ 20.15 $ 22.31 $ 22.31 Exercise price $ 20.15 $ 22.31 $ 22.31 Expected volatility (%) 100 % 100 % 105 % Expected life (years) 6.1 6.1 5.5 Risk-free interest rate (%) 4.7 % 4.7 % 4.7 % Expected dividend yield — — — During the six months ended June 30, 2024 a total of 281,644 RSUs were granted to employees that joined the Group in the same period and to existing employees. The RSUs shall vest equally over a four-year period on each of the four anniversaries of the vesting start date until either the RSUs are fully vested or the RSUs holders’ continuous service terminates. The fair value of the RSUs is determined based on the share value per ordinary share at the grant date (or at the first trading day after the grant date if the Nasdaq Stock Exchange is not open on this date). The grant dates and share closing prices for grants during the first six months of 2024 were: January 2 ($ 25.87 ), February 1 ($ 29.95 ), March 1 ($ 24.16 ), April 11 ($ 22.31 ), April 15 ($ 20.15 ), May 1 ($ 24.57 ) and June 1 ($ 17.71 ), respectively. During the six months ended June 30, 2024, 226,150 RSUs were issued to existing and newly joining key Management. The RSUs shall vest over a four-year period, with 25 % of the aggregate number of RSUs vesting on the 12-month anniversary of the vesting commencement date, and thereafter 1/ 48 th of the aggregate number of RSUs vesting on each subsequent monthly anniversary of the vesting commencement date, subject to continuous service through each applicable vesting date. During the six months ended June 30, 2024 , 23,335 RSUs were issued to members of the Board of Directors. The RSUs shall vest on the 12-month anniversary of the vesting start date. For the six months ended June 30, 2024, the Group recognized € 6.3 million of share-based payment expense in the unaudited condensed consolidated statement of income or loss and other comprehensive income (six months ended June 30, 2023: € 5.3 million ).

Basic and diluted loss per shar

Basic and diluted loss per share	6 Months Ended
	Jun. 30, 2024
Basic And Diluted Earnings Per Share1 [Abstract]
Basic and diluted loss per share	19. Basic and diluted loss per share Basic and diluted loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of issued and outstanding ordinary shares during the three and six months ended June 30, 2024 and 2023. All of the Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share attributable to ordinary stockholders as the effect of including them would be antidilutive. For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Net Loss ( 29,731,073 ) ( 21,897,873 ) ( 57,749,829 ) ( 44,528,822 ) Weighted average number of ordinary shares outstanding 53,939,597 34,556,017 53,843,789 34,191,993 Basic and diluted loss per share ( 0.55 ) ( 0.63 ) ( 1.07 ) ( 1.30 )

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Disclosure Of Commitments And Contingencies [Abstract]
Commitments and Contingencies	20. Commitments and Contingencies Claims There are no material claims known to management related to the activities of the Group. Commitments The Group’s contractual obligations and commitments as of June 30, 2024 amounted to € 95.4 million , (December 31, 2023: € 49 million) primarily related to research and development commitments. The Group had no contingent liabilities and no contingent assets as of June 30, 2024 and December 31, 2023.

Related parties

Related parties	6 Months Ended
	Jun. 30, 2024
Disclosure of transactions between related parties [abstract]
Related parties	21. Related parties Note 1.2 provides information about the Group’s structure, including details of the subsidiaries and the holding company. The following provides the total amount of transactions that have been entered into with related parties for the relevant financial period. Key management personnel compensation For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Short term employee benefits 1,300,557 1,092,741 2,661,986 2,176,182 Post employee benefits 62,130 43,090 126,189 93,521 Share-based payments 2,088,045 1,699,794 3,400,920 3,224,788 Total 3,450,732 2,835,625 6,189,095 5,494,491 Refer to note 18 for disclosures on the share-based payments related to RSUs and Options granted to key management during the six months ended June 30, 2024. The Group engages two management entities for the purpose of providing key management services to the Group. These management entities are considered related parties, as they provide key management services and key management personnel which have key management functions within these entities. Certain key management personnel are also shareholders of the Company. The aggregate amount of expense recognized in the unaudited condensed consolidated interim financial statements related to these related parties were € 0.3 million and € 0.6 million in the three and six months ended June 30, 2024 (2023: € 0.3 million; € 0.5 million), respectively. The outstanding balances payable to key management personnel, or entities which they control, as per six months ended June 30, 2024 and December 31, 2023 , were € 0.6 million and € 1.4 million, respectively.

Events after the reporting peri

Events after the reporting period	6 Months Ended
	Jun. 30, 2024
Disclosure of non-adjusting events after reporting period [abstract]
Events after the reporting period	22. Events after the reporting period The Company has evaluated subsequent events through August 13, 2024, which is the date the condensed consolidated interim financial statements were authorized for issuance, and did not identify any significant event after reporting period that needs to be disclosed.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2024
Disclosure of voluntary change in accounting policy [abstract]
Basis of preparation	2.1 Basis of preparation The unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board (IASB) and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended December 31, 2023 (“last annual financial statements”). These unaudited condensed consolidated interim financial statements do not include all the information required for a complete set of financial statements prepared in accordance with IFRS as issued by the IASB. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance since the last annual financial statements. The unaudited condensed consolidated interim financial statements have been prepared on a historical cost basis. Unless otherwise stated, the unaudited condensed consolidated interim financial statements are presented in euros and all values are rounded to the nearest EUR (€), except per share amounts.
Going concern	2.2 Going concern Management assessed the Company’s ability to fund its operations for a period of at least one year after the date th e financial statements are issued. Management has not identified a material uncertainty relating to the Company’s ability to continue as a going concern for a period of at least a year from the issuance of these financial statements. The financial statements of the Company have been prepared on the basis of the going concern assumption based on its existing funding, taking into account the Company’s current cash position and the projected cash flows based on the activities under execution on the basis of Pharvaris’ business plan and budget.
Use of judgements and estimates	2.3 Use of judgements and estimates In preparing these unaudited condensed consolidated interim financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.
Change in material accounting policies	2.4 Change in material accounting policies The accounting policies applied in these unaudited condensed consolidated interim financial statements are the same as those applied in the consolidated financial statements for the year ended December 31, 2023. New standards and interpretations issued not yet effective In April 2024, the IASB issued IFRS 18 Presentation and Disclosure in Financial Statements (“IFRS 18”) which replaces IAS 1 Presentation of Financial Statements. IFRS 18 requires an entity to classify all income and expenses within its statement of profit or loss into one of five categories: operating; investing; financing; income taxes; and discontinued operations. The first three categories are new. These categories are complemented by the requirement to present subtotals and totals for “operating profit or loss”, “profit or loss before financing income and taxes” and “profit or loss”. IFRS 18, and the amendments to the other standards, is effective for reporting periods beginning on or after January 1, 2027, but earlier application is permitted. The Group is currently evaluating the impact of this amendment. There are no other IFRS or IFRIC interpretations that are not yet effective and that are expected to have a material impact to the interim consolidated financial statements.

Corporate and Group informati_2

Corporate and Group information (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure Of Corporate And Group Information [Abstract]
Summary of Subsidiaries	The unaudited condensed consolidated interim financial statements of the Group include: Country of % of equity interest as Name Legal seat incorporation 2024 2023 Pharvaris Holdings B.V. Leiden The Netherlands 100 % 100 % Pharvaris Netherlands B.V. Leiden The Netherlands 100 % 100 % Pharvaris GmbH Zug Switzerland 100 % 100 % Pharvaris, Inc. Delaware United States of America 100 % 100 %

Research and development expe_2

Research and development expenses (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure Of Detailed Information Research And Development Expenses [Abstract]
Schedule of Breakdown of Research and Development Expenses	For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Clinical expenses ( 15,065,644 ) ( 7,629,432 ) ( 22,387,056 ) ( 12,497,879 ) Personnel expenses (Note 5) ( 6,450,500 ) ( 4,544,244 ) ( 11,630,976 ) ( 8,761,944 ) Manufacturing costs ( 1,572,017 ) ( 736,427 ) ( 4,135,971 ) ( 2,643,513 ) Nonclinical expenses 130,020 ( 1,667,811 ) ( 1,705,446 ) ( 4,419,009 ) License costs — — ( 1,500,000 ) — Intellectual Property costs ( 109,793 ) ( 104,021 ) ( 221,501 ) ( 104,021 ) ( 23,067,934 ) ( 14,681,935 ) ( 41,580,950 ) ( 28,426,366 )

General and administrative ex_2

General and administrative expenses (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure Of Detailed Information General And Administrative Expenses [Abstract]
Breakdown of General and Administrative Expenses	For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Personnel expenses (Note 5) ( 4,407,998 ) ( 3,434,343 ) ( 7,678,193 ) ( 6,735,927 ) Professional fees ( 2,155,727 ) ( 1,294,705 ) ( 3,332,956 ) ( 2,177,175 ) Facilities, communication & office expenses ( 1,466,955 ) ( 1,419,334 ) ( 3,147,222 ) ( 2,910,607 ) Accounting, tax and auditing fees ( 850,599 ) ( 537,961 ) ( 2,104,685 ) ( 897,314 ) Consulting fees ( 732,951 ) ( 126,447 ) ( 859,476 ) ( 304,316 ) Travel expenses ( 399,111 ) ( 455,717 ) ( 1,023,140 ) ( 778,450 ) Other expenses ( 1,300,726 ) ( 504,923 ) ( 2,967,238 ) ( 1,301,237 ) ( 11,314,067 ) ( 7,773,430 ) ( 21,112,910 ) ( 15,105,026 )

Personnel expenses (Tables)

Personnel expenses (Tables)	6 Months Ended
	Jun. 30, 2024
Personnel Expenses [Abstract]
Summary of Personnel Expenses	For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Wages and salaries ( 5,953,069 ) ( 4,618,862 ) ( 11,023,525 ) ( 8,823,246 ) Pension charges ( 357,282 ) ( 271,140 ) ( 751,915 ) ( 560,023 ) Other social security charges ( 660,711 ) ( 371,658 ) ( 1,245,426 ) ( 814,788 ) Share-based payments ( 3,887,436 ) ( 2,716,927 ) ( 6,288,303 ) ( 5,299,814 ) ( 10,858,498 ) ( 7,978,587 ) ( 19,309,169 ) ( 15,497,871 )

Finance income_(expense) (Table

Finance income/(expense) (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure Of Financial Income [Abstract]
Summary of Financial Income /(Expenses)	For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Foreign exchange differences 2,616,719 667,710 3,138,970 ( 927,768 ) Interest income over bank balances 2,114,635 ( 11,161 ) 2,178,556 95,366 Other finance expenses ( 9,803 ) ( 4,879 ) ( 17,755 ) ( 10,193 ) 4,721,551 651,670 5,299,771 ( 842,595 )

Income taxes (Tables)

Income taxes (Tables)	6 Months Ended
	Jun. 30, 2024
Income Taxes [Abstract]
Summary of Income Tax Expense	For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Income tax expense ( 70,623 ) ( 94,178 ) ( 355,740 ) ( 154,835 ) Income tax expense ( 70,623 ) ( 94,178 ) ( 355,740 ) ( 154,835 )
Summary of Reconciliation of Income Tax Benefit And The Accounting Loss	Reconciliation of income tax benefit at statutory tax rate and the income tax expense as reported in the unaudited condensed consolidated statement of profit or loss and other comprehensive income is as follows: For the three months ended June 30, For the six months ended 2024 2023 2024 2023 € € € € Loss before income tax ( 29,660,450 ) ( 21,803,695 ) ( 57,394,089 ) ( 44,373,987 ) Income tax against statutory rate in The Netherlands ( 25.8 %) 7,652,396 5,625,353 14,807,675 11,448,489 Effect of tax rates in other countries ( 4,260,352 ) ( 3,135,934 ) ( 8,412,880 ) ( 6,380,538 ) Deferred tax assets recognition effects ( 3,224,214 ) ( 2,473,007 ) ( 6,007,203 ) ( 4,989,138 ) Non-deductible expenses ( 238,743 ) ( 110,591 ) ( 573,609 ) ( 233,648 ) Prior period adjustments 290 — ( 169,723 ) — Total tax charge ( 70,623 ) ( 94,178 ) ( 355,740 ) ( 154,835 )

Property, plant and equipment (

Property, plant and equipment (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of detailed information about property, plant and equipment [abstract]
Summary of Property, Plant and Equipment	June 30, 2024 December 31, 2023 Net book value € € Balance at beginning of period 223,678 193,474 Additions 70,844 90,051 Depreciation expenses ( 35,971 ) ( 59,847 ) Balance at end of period 258,551 223,678 June 30, 2024 December 31, 2023 Cumulative depreciation € € As of January 1, ( 125,373 ) ( 65,526 ) Depreciation ( 35,971 ) ( 59,847 ) Balance at end of period ( 161,344 ) ( 125,373 ) June 30, 2024 December 31, 2023 Cumulative Costs € € Balance at beginning of period 349,051 259,000 Additions 70,844 90,051 Balance at end of period 419,895 349,051

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure Of Leases [Abstract]
Summary of information about right of use assets	The following table provides information about the Group’s right-of-use assets: June 30, December 31, 2023 € € Balance at beginning of period 231,893 432,965 Addition — ( 3,302 ) Depreciation charges ( 99,062 ) ( 197,770 ) Impact of transaction of foreign currency 1,150 — Balance at end of period 133,981 231,893
Summary of information about lease lease liabilities	The following table provides information about the Group’s lease liabilities at June 30, 2024: June 30, December 31, € € Office leases ( 140,378 ) ( 238,905 ) Total lease liability ( 140,378 ) ( 238,905 ) Current portion ( 96,628 ) ( 195,341 ) Non-current portion ( 43,750 ) ( 43,564 )

Receivables (Tables)

Receivables (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of acquired receivables [abstract]
Summary of Receivables	June 30, December 31, € € Current tax receivable 1,095,589 615,538 VAT receivables 515,304 423,486 1,610,893 1,039,024

Other current assets (Tables)

Other current assets (Tables)	6 Months Ended
	Jun. 30, 2024
Other Current Assets [Abstract]
Summary of Other Current Assets	June 30, December 31, € € Prepayments 5,921,334 4,959,889 Other assets — 620,815 5,921,334 5,580,704

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [abstract]
Summary of Share Capital	Issued shares June 30, December 31, Number of shares Number of shares Ordinary shares 54,007,711 52,290,212 54,007,711 52,290,212

Trade and other payables (Table

Trade and other payables (Tables)	6 Months Ended
	Jun. 30, 2024
Trade and other payables [abstract]
Summary of Trade and Other Liabilities	June 30, December 31, € € Trade payables 2,968,446 2,909,725 2,968,446 2,909,725

Accrued liabilities (Tables)

Accrued liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of Accrued liabilities [Abstract]
Summary of Accrued Liabilities	June 30, December 31, € € Consulting, professional and audit liability 1,933,366 351,064 Clinical accrued liabilities 8,154,946 1,832,590 Manufacturing accrued liabilities 1,108,601 2,079,900 Nonclinical accrued liabilities 618,128 493,907 Personnel related accruals 3,594,600 5,892,087 Other accrued liabilities 447,971 417,962 15,857,612 11,067,510

Share-based payments (Tables)

Share-based payments (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Summary of Changes in Stock Options and Restricted Stock Units	Set out below is an overview of changes in the Stock Options an d Restricted Stock Units (“RSUs”) during the six months ended June 30, 2024. Stock Options RSUs Outstanding Weighted Outstanding $ Outstanding January 1, 2024 3,830,652 9.46 1,033,814 Granted 785,000 21.68 531,129 Exercised (Vested and Settled) ( 234,694 ) 2.29 ( 157,989 ) Forfeited ( 159,687 ) 15.80 ( 127,543 ) Outstanding June 30, 2024 4,221,271 13.29 1,279,411
Summary of Fair Value Per Option at Each Grant/Measurements Date Using the Black-Scholes Formula	The inputs and outputs used in the measurement of the fair value per option at each grant/ measurement date using the Black-Scholes formula (including the related number of options and the fair value of the options) were as follows: April 15, 2024 April 11, April 11, Number of options 230,000 485,000 70,000 Fair value of the options $ 16.37 $ 18.12 $ 18.05 Fair value of the ordinary shares $ 20.15 $ 22.31 $ 22.31 Exercise price $ 20.15 $ 22.31 $ 22.31 Expected volatility (%) 100 % 100 % 105 % Expected life (years) 6.1 6.1 5.5 Risk-free interest rate (%) 4.7 % 4.7 % 4.7 % Expected dividend yield — — —

Basic and diluted loss per sh_2

Basic and diluted loss per share (Tables)	6 Months Ended
	Jun. 30, 2024
Basic And Diluted Earnings Per Share1 [Abstract]
Summary of Earnings Per Share	For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Net Loss ( 29,731,073 ) ( 21,897,873 ) ( 57,749,829 ) ( 44,528,822 ) Weighted average number of ordinary shares outstanding 53,939,597 34,556,017 53,843,789 34,191,993 Basic and diluted loss per share ( 0.55 ) ( 0.63 ) ( 1.07 ) ( 1.30 )

Related parties (Tables)

Related parties (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of transactions between related parties [abstract]
Summary of Compensation to Key Management Personnel	Key management personnel compensation For the three months ended June 30, For the six months ended June 30, 2024 2023 2024 2023 € € € € Short term employee benefits 1,300,557 1,092,741 2,661,986 2,176,182 Post employee benefits 62,130 43,090 126,189 93,521 Share-based payments 2,088,045 1,699,794 3,400,920 3,224,788 Total 3,450,732 2,835,625 6,189,095 5,494,491

Corporate and Group informati_3

Corporate and Group information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2024
Disclosure Of Corporate And Group Information [Abstract]
Entity incorporation, date of incorporation	Sep. 30, 2015

Corporate and Group informati_4

Corporate and Group information - Summary of Subsidiaries (Detail)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Pharvaris Holdings BV [member]
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name	Pharvaris Holdings B.V.
Legal seat	Leiden
Country of incorporation	The Netherlands
% of equity interest	100%	100%
Pharvaris Netherlands BV [member]
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name	Pharvaris Netherlands B.V.
Legal seat	Leiden
Country of incorporation	The Netherlands
% of equity interest	100%	100%
Pharvaris GmbH [member]
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name	Pharvaris GmbH
Legal seat	Zug
Country of incorporation	Switzerland
% of equity interest	100%	100%
Pharvaris Inc [member]
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name	Pharvaris, Inc.
Legal seat	Delaware
Country of incorporation	United States of America
% of equity interest	100%	100%

Research and development expe_3

Research and development expenses - Breakdown of Research and Development Expenses (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	€ (23,067,934)	€ (14,681,935)	€ (41,580,950)	€ (28,426,366)
Clinical expenses [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	(15,065,644)	(7,629,432)	(22,387,056)	(12,497,879)
Personnel expenses [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	(6,450,500)	(4,544,244)	(11,630,976)	(8,761,944)
Manufacturing costs [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	(1,572,017)	(736,427)	(4,135,971)	(2,643,513)
Nonclinical expenses [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	(130,020)	(1,667,811)	(1,705,446)	(4,419,009)
License costs [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses			(1,500,000)
Intellectual Property costs [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research and development expenses	€ (109,793)	€ (104,021)	€ (221,501)	€ (104,021)

General and administrative ex_3

General and administrative expenses - Breakdown of General and Administrative Expenses (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure Of Detailed Information General And Administrative Expenses [Abstract]
Personnel expenses (Note 5)	€ (4,407,998)	€ (3,434,343)	€ (7,678,193)	€ (6,735,927)
Professional fees	(2,155,727)	(1,294,705)	(3,332,956)	(2,177,175)
Facilities, communication & office expenses	(1,466,955)	(1,419,334)	(3,147,222)	(2,910,607)
Accounting, tax and auditing fees	(850,599)	(537,961)	(2,104,685)	(897,314)
Consulting fees	(732,951)	(126,447)	(859,476)	(304,316)
Travel expenses	(399,111)	(455,717)	(1,023,140)	(778,450)
Other expenses	(1,300,726)	(504,923)	(2,967,238)	(1,301,237)
Total	€ (11,314,067)	€ (7,773,430)	€ (21,112,910)	€ (15,105,026)

General and administrative ex_4

General and administrative expenses - Additional Information (Detail) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Disclosure Of Detailed Information General And Administrative Expenses [Abstract]
Depreciation Property Plant And Equipment And Short Term Leases	€ 0.1	€ 0.1

Personnel expenses - Summary of

Personnel expenses - Summary of Personnel Expenses (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure Of Expenses By Nature [Abstract]
Wages and salaries	€ (5,953,069)	€ (4,618,862)	€ (11,023,525)	€ (8,823,246)
Pension charges	(357,282)	(271,140)	(751,915)	(560,023)
Other social security charges	(660,711)	(371,658)	(1,245,426)	(814,788)
Share-based payments	(3,887,436)	(2,716,927)	(6,288,303)	(5,299,814)
Total	€ (10,858,498)	€ (7,978,587)	€ (19,309,169)	€ (15,497,871)

Personnel expenses - Additiona

Personnel expenses - Additional Information (Detail) - Staff	Jun. 30, 2024	Jun. 30, 2023
Disclosure Of Expenses By Nature [Abstract]
Number of employees	83	68

Finance income_(expense) - Summ

Finance income/(expense) - Summary of Financial Income/ ( Expenses) (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure Of Financial Expenses [Abstract]
Foreign exchange differences	€ 2,616,719	€ 667,710	€ 3,138,970	€ (927,768)
Interest income over bank balances	2,114,635	(11,161)	2,178,556	95,366
Other finance expenses	(9,803)	(4,879)	(17,755)	(10,193)
Total finance (expenses)/income	€ 4,721,551	€ 651,670	€ 5,299,771	€ (842,595)

Income taxes - Summary of Incom

Income taxes - Summary of Income Tax Expense (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Major components of tax expense (income) [abstract]
Income tax expense	€ (70,623)	€ (94,178)	€ (355,740)	€ (154,835)
Income tax expense	€ (70,623)	€ (94,178)	€ (355,740)	€ (154,835)

Income taxes - Summary of Recon

Income taxes - Summary of Reconciliation of Income Tax Benefit And The Accounting Loss (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Loss before income tax	€ (29,660,450)	€ (21,803,695)	€ (57,394,089)	€ (44,373,987)
Income tax against statutory rate in The Netherlands (25.8%)	7,652,396	5,625,353	14,807,675	11,448,489
Effect of tax rates in other countries	(4,260,352)	(3,135,934)	(8,412,880)	(6,380,538)
Deferred tax assets recognition effects	(3,224,214)	(2,473,007)	(6,007,203)	(4,989,138)
Non-deductible expenses	(238,743)	(110,591)	(573,609)	(233,648)
Prior period adjustments	290	0	(169,723)	0
Total tax charge	€ (70,623)	€ (94,178)	€ (355,740)	€ (154,835)

Income taxes - Summary of Rec_2

Income taxes - Summary of Reconciliation of Income Tax Benefit And The Accounting Loss (Parenthetical) (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Reconciliation of average effective tax rate and applicable tax rate [abstract]
Applicable tax rate	25.80%	25.80%	25.80%	25.80%

Income taxes - Additional Infor

Income taxes - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Reconciliation of average effective tax rate and applicable tax rate [abstract]
Effective tax rate	0.60%	(0.30%)

Property, plant and equipment -

Property, plant and equipment - Summary of Property, Plant and Equipment (Detail) - EUR (€)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Disclosure Of Property Plant And Equipment [Line Items]
Balance at beginning of period	€ 223,678	€ 193,474
Additions	70,844	90,051
Depreciation expenses	(35,971)	(59,847)
Balance at end of period	258,551	223,678
Cumulative depreciation [member]
Disclosure Of Property Plant And Equipment [Line Items]
Balance at beginning of period	(125,373)	(65,526)
Depreciation expenses	(35,971)	(59,847)
Balance at end of period	(161,344)	(125,373)
Cumulative Costs [member]
Disclosure Of Property Plant And Equipment [Line Items]
Balance at beginning of period	349,051	259,000
Additions	70,844	90,051
Balance at end of period	€ 419,895	€ 349,051

Property, plant and equipment_2

Property, plant and equipment - Additional Information (Detail) - EUR (€)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Disclosure of detailed information about property, plant and equipment [abstract]
Acquired assets	€ 70,844	€ 90,051

Leases - Summary of information

Leases - Summary of information about right of use assets (Detail) - EUR (€)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Disclosure Of Leases [Abstract]
Balance at beginning of period	€ 231,893	€ 432,965
Addition		(3,302)
Depreciation charges	(99,062)	(197,770)
Impact of transaction of foreign currency	1,150
Balance at end of period	€ 133,981	€ 231,893

Leases - Summary of informati_2

Leases - Summary of information about lease lease liabilities (Detail) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Disclosure Of Lease Liabilities [Line Items]
Lease liabilities	€ (140,378)	€ (238,905)
Current portion	(96,628)	(195,341)
Non-current portion	(43,750)	(43,564)
Office Lease [Member]
Disclosure Of Lease Liabilities [Line Items]
Lease liabilities	€ (140,378)	€ (238,905)

Leases - Additional Information

Leases - Additional Information (Detail) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Disclosure Of Leases [Abstract]
Lease Agreement Term	3 years
Cash outflow for leases	€ 100	€ 90

Receivables - Summary of Receiv

Receivables - Summary of Receivables (Detail) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Disclosure of acquired receivables [abstract]
Current tax receivable	€ 1,095,589	€ 615,538
VAT receivables	515,304	423,486
Total	€ 1,610,893	€ 1,039,024

Other current assets - Summary

Other current assets - Summary of Other Current Assets (Detail) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Other Current Assets [Abstract]
Prepayments	€ 5,921,334	€ 4,959,889
Other assets	0	620,815
Total	€ 5,921,334	€ 5,580,704

Equity - Additional Information

Equity - Additional Information (Detail) € / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended	6 Months Ended
	Apr. 30, 2024 USD ($)	Jan. 31, 2024 USD ($) shares	Mar. 31, 2022 USD ($)	Jun. 30, 2024 EUR (€) € / shares shares	Jun. 30, 2024 USD ($)	Jun. 30, 2023 EUR (€)	Dec. 31, 2023 EUR (€) shares
Disclosure of classes of share capital [line items]
Number of shares issued and fully paid				54,007,711			52,290,212
Nominal value per share | € / shares				€ 0.12
Proceeds from issue of ordinary shares				€ 9,300,000	$ 9,800
Authorized share capital | €				14,100,000
Share capital | €				6,480,925		€ 4,900,000	€ 6,274,833
Proceeds from sales			$ 350,000	632,737		€ 64,084,953
Proceeds from exercise of pre-funded warrants | $		$ 10
Issuance of ordinary shares		1,375,000
Leerink Partners [member]
Disclosure of classes of share capital [line items]
At-the-market program providing for sales from time to time | $	$ 175,000
Payments for share issue costs				€ 300,000	$ 300
Ordinary shares [member]
Disclosure of classes of share capital [line items]
Number of shares issued and fully paid				54,007,711			52,290,212
Sale of shares				593,927
Number of shares authorized				117,500,000
Ordinary shares [member] | S V B Leerink [Member]
Disclosure of classes of share capital [line items]
At-the-market program providing for sales from time to time | $			$ 75,000

Equity - Summary of Share Capit

Equity - Summary of Share Capital (Detail) - shares	Jun. 30, 2024	Dec. 31, 2023
Disclosure of classes of share capital [line items]
Number of shares issued and fully paid	54,007,711	52,290,212
Ordinary shares [member]
Disclosure of classes of share capital [line items]
Number of shares issued and fully paid	54,007,711	52,290,212

Trade and other payables - Summ

Trade and other payables - Summary of Trade and Other Liabilities (Detail) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Trade and other payables [abstract]
Trade payables	€ 2,968,446	€ 2,909,725
Total Trade And Other Payables	€ 2,968,446	€ 2,909,725

Accrued liabilities - Summary o

Accrued liabilities - Summary of Accrued Liabilities (Detail) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Disclosure of financial liabilities [line items]
Accrued liabilities	€ 15,857,612	€ 11,067,510
Consulting Professional And Audit Liability [Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	1,933,366	351,064
Clinical Accrued Liabilities [Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	8,154,946	1,832,590
Manufacturing Accrued Liabilities [Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	1,108,601	2,079,900
Nonclinical Accrued Liabilities [Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	618,128	493,907
Personnel Related Accruals [Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	3,594,600	5,892,087
Other Accrued Liabilities [Member]
Disclosure of financial liabilities [line items]
Accrued liabilities	€ 447,971	€ 417,962

Share-based Payments - Summary

Share-based Payments - Summary of Changes in Stock Options and Restricted Stock Units (Detail)	6 Months Ended
	Jun. 30, 2024 shares $ / shares
Stock Options [Member]
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items]
Beginning balance	3,830,652
Granted	785,000
Exercised (Vested and Settled)	(234,694)
Forfeited	(159,687)
Ending balance	4,221,271
Beginning balance, Weighted average | $ / shares	$ 9.46
Granted , Weighted average | $ / shares	21.68
Exercised (Vested and Settled) , Weighted average | $ / shares	2.29
Forfeited , Weighted average | $ / shares	15.8
Ending balance , Weighted average | $ / shares	$ 13.29
Restricted Stock Units [Member]
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items]
Beginning balance	1,033,814
Granted	531,129
Exercised (Vested and Settled)	(157,989)
Forfeited	(127,543)
Ending balance	1,279,411

Share-based Payments - Summar_2

Share-based Payments - Summary of Fair Value Per Option at Each Grant/Measurements Date Using the Black-Scholes Formula (Detail)	Jun. 01, 2024 $ / shares	May 01, 2024 $ / shares	Apr. 15, 2024 yr shares € / shares $ / shares	Apr. 15, 2024 yr shares € / shares	Apr. 11, 2024 yr shares € / shares $ / shares	Apr. 11, 2024 yr shares € / shares	Mar. 01, 2024 $ / shares	Feb. 01, 2024 $ / shares	Jan. 02, 2024 $ / shares
Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]
Exercise price | $ / shares	$ 17.71	$ 24.57	$ 20.15		$ 22.31		$ 24.16	$ 29.95	$ 25.87
Key management personnel of entity or parent [member]
Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]
Exercise price | $ / shares			$ 20.15		22.31
Stock options granted to board of directors [Member]
Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]
Exercise price | $ / shares					$ 22.31
Black-Scholes formula [member] | Key management personnel of entity or parent [member]
Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]
Number of options | shares			230,000	230,000	485,000	485,000
Fair value of the options			$ 16.37	€ 16.37	$ 18.12	€ 18.12
Fair value of the ordinary shares			$ 20.15	20.15	$ 22.31	22.31
Exercise price				€ 20.15		€ 22.31
Expected volatility			100%	100%	100%	100%
Expected life | yr			6.1	6.1	6.1	6.1
Risk-free interest rate			4.70%	4.70%	4.70%	4.70%
Expected dividend yield			0%	0%	0%	0%
Black-Scholes formula [member] | Stock options granted to board of directors [Member]
Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]
Number of options | shares					70,000	70,000
Fair value of the options					$ 18.05	€ 18.05
Fair value of the ordinary shares					$ 22.31	22.31
Exercise price						€ 22.31
Expected volatility					105%	105%
Expected life | yr					5.5	5.5
Risk-free interest rate					4.70%	4.70%
Expected dividend yield					0%	0%

Share-based Payments - Additio

Share-based Payments - Additional Information (Detail) $ / shares in Units, € in Millions, $ in Millions								6 Months Ended
	Jun. 01, 2024 $ / shares	May 01, 2024 $ / shares	Apr. 15, 2024 shares $ / shares	Apr. 11, 2024 shares $ / shares	Mar. 01, 2024 $ / shares	Feb. 01, 2024 $ / shares	Jan. 02, 2024 $ / shares	Jun. 30, 2024 EUR (€) shares	Jun. 30, 2023 USD ($) shares
statement of Lineitems [Line Items]
Weighted average share price | $ / shares	$ 17.71	$ 24.57	$ 20.15	$ 22.31	$ 24.16	$ 29.95	$ 25.87
Number of share options exercisable in share-based payment arrangement								4,221,271	2,065,270
Expense from share-based payment transactions								€ 6.3	$ 5.3
Key management personnel of entity or parent [member]
statement of Lineitems [Line Items]
Number of instruments granted in share based payment arrangement			230,000	485,000
Description of maximum term of options granted for share-based payment arrangement			April 15, 2034	April 11, 2034
Weighted average share price | $ / shares			$ 20.15	$ 22.31
Percentage of aggregate number of stock options shall vest on one year at grant date			25%	25%
Percentage of aggregate number of stock options shall vest on One Month at grant date			48%	48%
Key management personnel of entity or parent [member] | Restricted Stock Units [Member]
statement of Lineitems [Line Items]
Number of instruments granted in share based payment arrangement								226,150
Percentage of aggregate number of stock options shall vest on one year at grant date								25%
Percentage of aggregate number of stock options shall vest on One Month at grant date								48%
Employees [Member] | Restricted Stock Units [Member]
statement of Lineitems [Line Items]
Number of instruments granted in share based payment arrangement								281,644
Stock options granted to board of directors [Member]
statement of Lineitems [Line Items]
Number of instruments granted in share based payment arrangement				70,000
Description of maximum term of options granted for share-based payment arrangement				April 11, 2034
Weighted average share price | $ / shares				$ 22.31
Percentage of aggregate number of stock options shall vest on one year at grant date				100%
Stock options granted to board of directors [Member] | Restricted Stock Units [Member]
statement of Lineitems [Line Items]
Number of instruments granted in share based payment arrangement								23,335

Basic and diluted loss per sh_3

Basic and diluted loss per share - Summary of Earnings Per Share (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings per share [line items]
Net Loss	€ (29,731,073)	€ (21,897,873)	€ (57,749,829)	€ (44,528,822)
Weighted average number of ordinary shares outstanding	53,939,597	34,556,017	53,843,789	34,191,993
Basic loss per share	€ (0.55)	€ (0.63)	€ (1.07)	€ (1.3)
Diluted loss per share	€ (0.55)	€ (0.63)	€ (1.07)	€ (1.3)

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Disclosure of other provisions [abstract]
Contingent liabilities	€ 0	€ 0
Contingent assets	0	0
Material claims known to management related to the activities of the group	0
Contractual obligations and commitments	€ 95,400,000	€ 49,000,000

Related parties - Additional in

Related parties - Additional information (Detail) - Key management personnel of entity or parent [member] - EUR (€) € in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure Of Information About Key Management Personnel [Line Items]
Related party expenses recognized in interim financial statements paid to external management entities	€ 0.3	€ 0.3	€ 0.6	€ 0.5
Amount of outstanding payable	€ 0.6		€ 0.6		€ 1.4

Related parties - Summary of Co

Related parties - Summary of Compensation to Key Management Personnel (Detail) - EUR (€)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of transactions between related parties [abstract]
Short term employee benefits	€ 1,300,557	€ 1,092,741	€ 2,661,986	€ 2,176,182
Post employee benefits	62,130	43,090	126,189	93,521
Share-based payments	2,088,045	1,699,794	3,400,920	3,224,788
Total	€ 3,450,732	€ 2,835,625	€ 6,189,095	€ 5,494,491